US OptionsDetailed Quotes

THTX250117P5000

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Dec 27 09:30 ET
0.00High0.00Low

Theratechnologies Stock Discussion

Sign in to post a comment
    Jaguar8
    Jaguar8
    Dec 15 20:58
    🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order
    $ABVC BioPharma (ABVC.US)$  - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
    $Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
    8
    7
    Jaguar8
    Jaguar8
    Dec 10 14:24
    NEWS
    $Theratechnologies (THTX.US)$
    Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
    Tuesday, 10th December at 3:15 pm
    MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug Administration (FDA) has assigned a Prescriptio...
    Jaguar8
    Jaguar8
    Dec 9 06:36
    NEWS
    $Theratechnologies (THTX.US)$
    Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
    No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients
    Preliminary evidence of dose response includes significant tumor shrinkage and one patient with complete resolution of a liver lesion
    MONTREAL, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologie...
    Trytosaveabit
    Trytosaveabit
    Dec 4 06:43
    Update
    $Theratechnologies (THTX.US)$ Theratechnologies Brief: Announcing Exclusive Licensing Agreement With Ionis to Commercialize Olezarsen and Donidalorsen in Canada
    MT Newswires· 4 mins ago
    Jaguar8
    Jaguar8
    Dec 3 15:30
    NEWS
    $Theratechnologies (THTX.US)$
    Theratechnologies Announces Resumed Production of EGRIFTA SV®
    Tuesday, 3rd December at 4:30 pm
    MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the production of EGRIFTA SV® has resumed following a voluntary shutdown of the Company's contract manufacturer's fa...
    Jaguar8
    Jaguar8
    Dec 2 06:40
    NEWS
    $Theratechnologies (THTX.US)$
    Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
    Monday, 2nd December at 7:30 am
    • New financing replaces existing credit facility to optimize Company's capital structure
    • Favorable interest rates and amortization schedules to free up approximately $19 million in cash in 2025 to support business development strategy
    2
    Jaguar8
    Jaguar8
    Oct 17 14:54
    NEWS
    $Theratechnologies (THTX.US)$
    Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
    Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) presented data at IDWeek 2024 highlighting the impact of excess visceral abdominal fat (EVAF) on cardiovascular disease (CVD) risk in people with HIV (PWH). Two studies were presented:
    1. The VAMOS study showed that EVAF is prevalent (58%) in PWH on modern anti-r...
    Jaguar8
    Jaguar8
    Oct 10 06:31
    NEWS
    $Theratechnologies (THTX.US)$
    Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
    • Q3 revenue of $22.6 million represents +8% growth year-over-year
    • Positive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million
    • Fiscal 2024 guidance revised to between $83 and $85 million in revenue and Adjusted EBITDA guidance increased to a range of $17 to $19 million
    Jaguar8
    Jaguar8
    May 23 16:02
    $Theratechnologies (THTX.US)$
    NEWS
    Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
    Theratechnologies announced promising Phase 1 data for its investigational drug, sudocetaxel zendusortide, at the 2024 ASCO annual meeting.
    The drug showed long-term disease stabilization in patients with solid tumors, lasting up to 45 weeks even after treatment ceased.
    The study highlighted a uni...
    Jaguar8
    Jaguar8
    May 2 06:31
    $Theratechnologies (THTX.US)$
    NEWS
    Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
    05/02/2024 - 04:30 AM
    First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors
    Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing
    MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the...

No comment yet